ASM 024

Drug Profile

ASM 024

Alternative Names: ASM-024

Latest Information Update: 05 Jan 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asmacure
  • Developer Odan Laboratories
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action Muscarinic receptor modulators; Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Allergic asthma; Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Aug 2015 Odan Laboratories acquires Asmacure Ltee
  • 10 Aug 2015 Phase-II development is ongoing for ASM 024 as a dry powder for inhalation for Asthma and chronic obstructive pulmonary disease
  • 08 Feb 2015 Asmacure terminates a phase I/II trial in Asthma in Canada (Inhalation, powder) (NCT01793298)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top